Table 2 Relationships between microvessel invasion and clinicopathological features in the discovery cohort

Age, year

52.1 ± 11.6

53.3 ± 11.7

0.082

Gender, male/female

332 (85.3%)/57 (14.7%)

973 (84.5%)/178 (15.5%)

0.700

Hepatitis B history, yes/no

317 (83.6%)/62 (16.4%)

938 (83.0%)/192 (17.0%)

0.776

ALT, U/L

54.4 ± 84.7

50.7 ± 64.6

0.370

γ-GT, U/L

94.3 ± 84.9

86.9 ± 92.7

0.168

Albumin, g/L

40.9 ± 4.9

41.6 ± 4.6

0.010

Liver cirrhosis, yes/no

312 (81.0%)/73 (19.0%)

956 (84.3%)/178 (15.7%)

0.153

α-Fetoprotein (>200/≤200 ng/dL)

191 (49.1%)/198 (50.9%)

402 (34.9%)/749 (65.1%)

<0.001

Tumor size, cm

6.5 ± 3.8

4.9 ± 3.3

<0.001

Tumor size (>5 cm/≤5 cm)

195 (50.1%)/194 (49.9%)

370 (32.1%)/781 (67.9%)

<0.001

Tumor number, solitary/multiple

332 (85.3%)/57 (14.7%)

1009 (87.7%)/142 (12.3%)

0.239

Tumor encapsulation, complete/no

166 (42.9%)/221 (57.1%)

637 (55.4%)/512 (44.6%)

<0.001

Tumor differentiation, I–II/III–IV

232 (59.9%)/155 (40.1%)

866 (76.5%)/266 (23.5%)

<0.001

BCLC stage, 0/A/B

24 (6.2%)/312 (80.2%)/53 (13.6%)

170 (14.8%)/880 (76.5%)/101 (8.8%)

<0.001*